IBMD will be of strategic importance to Australian biomedical research and industry only if we focus our technology development to real-world need and produce materials and devices that address a particular need in the market. Successfully leveraging our technology against critical biomedical problems will allow world-leading research that will contribute to the fundamental knowledge base and will produce ground-breaking findings that will transform our understanding of normal development and disease.
We will collaborate with leading experts to provide technology that focuses on key health issues such as:
- Cardiovascular disease (31% of all global deaths (17.9 M in 2016)
- Cancer (2nd leading cause of death (9.6 M in 2018)),
- Diabetes (1.6 M deaths directly attributable to diabetes in 2016 and 422 Million people with diabetes in 2014) and
- Antibiotic resistance: an emerging and deeply worrying trend that could make many the medicines we currently rely on treat or control many infectious diseases. The scope of the issue is illustrated by the World Health Organisations statement that: “Without urgent action, we are heading for a post-antibiotic era, in which common infections and minor injuries can once again kill.”
